Opinion on Therapy Area in Germany

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: research shows value of early disease identification, but caution in treatment is advised

At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.

Published By Datamonitor
03 May 2012
CommentWire
CommentWire

AHP/Bayer: Baycol unlikely to mirror fen-phen

Published By Datamonitor
24 Oct 2001
Expert View
Expert View

Altana considers divesting pharma business

Following disappointing trial results in its respiratory pipeline, a failure to secure the US approval of Alvesco, and the breakdown of its collaboration with Pfizer over Daxas, all eyes are on Altana as rumors suggest it is considering selling its drugs unit. As yet, Altana has neither confirmed nor denied the rumors, which follow a disappointing year for the company's pharmaceutical unit.

Published By Datamonitor
21 Oct 2005
CommentWire
CommentWire

Altana: putting the feelers out for a suitable partner

German pharmaceutical firm Altana has reiterated that it will seek a suitable strategic partner for its pharma business following the separation from the chemical business later this year. This comes less than a month after German pharma giant Bayer announced its acquisition of second-place domestic pharma Schering AG, and could stir up further excitement among German bidders.

Published By Datamonitor
03 May 2006
CommentWire
CommentWire

Anadys: hepatitis C grant should boost research

The German government has awarded US-based biotech company Anadys a grant to identify proteins involved in hepatitis C transmission. Anadys' novel approach to drug development could well result in the development of more effective products, which would enhance the company's position in the anti-infectives field.

Published By Datamonitor
02 Jul 2002
ResearchWire
ResearchWire

Anticonvulsants: 12% usage rate for US migraine prophylaxis

Published By Datamonitor
12 Dec 2001
ResearchWire
ResearchWire

Anticonvulsants: 12% usage rate for US migraine prophylaxis

Published By Datamonitor
31 Jan 2002
ResearchWire
ResearchWire

Anticonvulsants: potential sales growth in off-label expansion

Published By Datamonitor
31 Jul 2001
ResearchWire
ResearchWire

Antidepressants: noradrenergics sales to rise

Published By Datamonitor
15 Mar 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.